# 2026-23541: FDA Seeks Comments on Lab Rules for Pre-Market Product Studies

2026-23541, Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Good Laboratory Practice Requirements for Nonclinical Laboratory Studies, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-11-19, effective Submit written comments (including recommendations) on the collection of information by December 21, 2026.; PRIA reads it as touching household money (as of 2026-11-19).

- Canonical: https://policyrisk.com/federal-register/2026-23541
- As of: 2026-11-19
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-23541
- Title: Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Good Laboratory Practice Requirements for Nonclinical Laboratory Studies
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 74585
- Published: 2026-11-19
- Effective: Submit written comments (including recommendations) on the collection of information by December 21, 2026.
- Comments close: 2026-12-21
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-11-19

## In one line

FDA Seeks Comments on Lab Rules for Pre-Market Product Studies

## Summary

The FDA is asking for public feedback on extending rules that make sure lab studies on food additives, drugs, and medical devices are done right and safely. This affects companies testing products before they hit the market, helping protect consumers without adding new costs. Comments are open until December 21, 2026, so now’s the time to weigh in!

## Abstract

The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

## Effects PRIA read

- GLP Recordkeeping and Reporting Continued: cost, high. If you sponsor or run nonclinical laboratory studies for products regulated by FDA (food additives, human drugs and biological products, animal drugs, or medical devices), you must continue to follow the Good Laboratory Practice rules in 21 CFR part 58 and retain required records and prepare final…
- No Capital or O&M Costs for GLP Collection: benefit, low. FDA states there are no capital costs or operating and maintenance (O&M) costs associated with this information collection (OMB control number 0910-0119). The agency is retaining the currently approved burden estimates rather than adding new cost categories.

## Related documents

- [2026-23351](https://policyrisk.com/federal-register/2026-23351): Rulemaking To Provide That N-acetyl-L-cysteine Is Not Excluded From the Dietary Supplement Definition, 2026-11-17
- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25

## Sources
- [2026-23541 on federalregister.gov](https://www.federalregister.gov/documents/2026/11/19/2026-23541/agency-information-collection-activities-submission-for-office-of-management-and-budget-review)
- [2026-23541 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-11-19/pdf/2026-23541.pdf)

## Related
- [Previous: 2026-23540, Medicare and Medicaid Programs; Quarterly Listing of Program Issuances-July Thr…](https://policyrisk.com/federal-register/2026-23540)
- [Next: 2026-23542, Agency Information Collection Activities; Submission for Office of Management a…](https://policyrisk.com/federal-register/2026-23542)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-23541 (as of 2026-11-19).
